A

Adverum Biotechnologies
D

ADVM

5.77000
USD
-0.39
(-6.33%)
Market Closed
Volume
10,691
EPS
-5
Div Yield
-
P/E
-1
Market Cap
120,021,210
OverviewSignalsIdeasNews
Related Instruments
    B
    BLUE
    -0.04270
    (-11.74%)
    0.32090 USD
    B
    BMRN
    -2.200
    (-3.35%)
    63.440 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    MRNA
    MRNA
    -2.950
    (-7.42%)
    36.830 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    V
    VYGR
    -0.57000
    (-9.18%)
    5.64000 USD
    More
News

Title: Adverum Biotechnologies

Sector: Healthcare
Industry: Biotechnology
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.